What is Abivax S.A. (ABVX)?

Abivax S.A. (ABVX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ABVX?

The current price of ABVX is $89.84. Prices are updated in real time on Stocks360.

What is ABVX's price-to-earnings (PE) ratio?

ABVX's trailing twelve-month PE ratio is -17.14, based on current price and earnings per share data available on Stocks360.

What is ABVX's market capitalization?

ABVX's market capitalization is $7,720,682,587.00, placing it in the mid-cap tier.

Abivax S.A. (ABVX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$89.84

Market Cap

$7.72B

PE (TTM)

-17.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.25

Day Range

$87.03 – $90.98

52-wk Range

$69.81 – $148.83

Avg Volume

N/A

Volume

533.42K

Abivax S.A. (ABVX) is a publicly traded company in the Healthcare sector. Latest price: $89.84. Market cap $7.72B. Trailing PE -17.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $98.94 2026-10-28 · $89.84 (-9.20%)

Earnings

Most Recent

Sep 21, 2026

EPS $-1.71 vs est. $-0.98

Missed by $0.73

Next Earnings

Dec 21, 2026

EPS estimate $-0.92

Proprietary Signals

Signal snapshot temporarily unavailable.

About Abivax S.A.

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-17.14×
P/S (TTM)	-3504.70×
P/B	17.56×
PEG	0.31×
P/FCF (TTM)	-47.88×
EV / EBITDA	-23.95×
EV / Sales	-3312.94×
Earnings Yield	-5.48%
Free Cash Flow Yield	-2.09%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.68B
Net Income (TTM)	-$387.71M
Free Cash Flow (TTM)	-$122.17M
Net Debt	-$386.78M
Working Capital	$355.94M
Gross Margin	153.15%
Operating Margin	11950.42%
Net Margin	17488.89%
Return on Equity	-85.88%
Return on Invested Capital	-60.98%